Pieris Pharmaceuticals (PIRS) - Dana dhuwit diétung saben saham

Pieris Pharmaceuticals (PIRS) possesses the potential for significant pricing power thanks to its Anticalin platform for targeted drug delivery. However, potential contract terminations with partners and a capital deficit create financial threats. The cash per share history clearly demonstrates liquidity, where the 16.15 level captures the current state. Diversified supply chains maintaining a strict cold chain ensure the continuity of research.
Rincian metrik komprehensif lan analitis Pieris Pharmaceuticals, Inc. (PIRS)

This metric is calculated by dividing total cash and cash equivalents by the number of shares outstanding, determining the intrinsic liquidity value available to the holder of each security. For Pieris Pharmaceuticals (PIRS), in the absence of profitable products and amid cost-cutting measures, this calculation reflects the capital burn rate. Analyzing the current liquidity per share allows for an assessment of the company's survival runway before additional capitalization becomes necessary.